These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 27193745)

  • 1. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
    Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
    J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.
    Walensky RP; Jacobsen MM; Bekker LG; Parker RA; Wood R; Resch SC; Horstman NK; Freedberg KA; Paltiel AD
    J Infect Dis; 2016 May; 213(10):1523-31. PubMed ID: 26681778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention.
    Glaubius RL; Parikh UM; Hood G; Penrose KJ; Bendavid E; Mellors JW; Abbas UL
    Open Forum Infect Dis; 2016 Sep; 3(3):ofw125. PubMed ID: 27703992
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
    Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
    J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
    Grant H; Gomez GB; Kripke K; Barnabas RV; Watts C; Medley GF; Mukandavire Z
    Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
    Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
    AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058.
    van de Vijver DAMC; Richter AK; Boucher CAB; Gunsenheimer-Bartmeyer B; Kollan C; Nichols BE; Spinner CD; Wasem J; Schewe K; Neumann A
    Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
    Alistar SS; Grant PM; Bendavid E
    BMC Med; 2014 Mar; 12():46. PubMed ID: 24629217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.
    Walensky RP; Park JE; Wood R; Freedberg KA; Scott CA; Bekker LG; Losina E; Mayer KH; Seage GR; Paltiel AD
    Clin Infect Dis; 2012 May; 54(10):1504-13. PubMed ID: 22474224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
    Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
    Long EF; Stavert RR
    J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
    Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
    Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study.
    Hu QH; Meyers K; Xu JJ; Chu ZX; Zhang J; Ding HB; Han XX; Jiang YJ; Geng WQ; Shang H
    BMC Infect Dis; 2019 Jul; 19(1):663. PubMed ID: 31345169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision.
    Mudimu E; Peebles K; Mukandavire Z; Nightingale E; Sharma M; Medley GF; Klein DJ; Kripke K; Bershteyn A
    PLoS One; 2020; 15(12):e0244761. PubMed ID: 33382803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
    Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
    Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.